Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing

PLEASANTON, Calif.: PLEASANTON, Calif., Dec. 30, 2021 /PRNewswire/ -- Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm. Other participating investors include Series B Co-leads GL Ventures (venture capital...

Click to view original post